循環過剰に起因する実験的肺動脈高血圧の予防のためのボセタン
Benoît Rondelet1, François Kerbaul, Sophie Motte
1Laboratory of Physiology, Free University of Brussels, Brussels, Belgium.
Circulation
|March 12, 2003
まとめ
二重のエンドセリン受容体対抗体ボセンタンは,エンドセリン-1系を阻害することによって,豚児の過剰循環誘発性肺高血圧を完全に予防します. この研究では,肺動脈高血圧の早期発症におけるエンドセリンの役割を明らかにしています.
科学分野:
- 心血管科学の研究について
- 肺高血圧の病理生理学 肺高血圧の病理生理学
- 薬理学 薬理学とは
背景:
- 肺動脈高血圧 (PAH) の治療には,エンドセリン受容体アンタゴニストが含まれていますが,PAHの病原性におけるエンドセリンの正確な役割は不明です.
- 初期のPAHのブタモデルにおけるエンドセリン-1 (ET-1),酸化窒素 (NO),および血管内皮成長因子 (VEGF) の役割を調査する.
研究 の 目的:
- 慢性的な全身から肺へのシャントリングによる肺高血圧の発症におけるET-1システムの関与を明らかにする.
- これらの病理的変化を予防または逆転させるための二重エンドセリン受容体抗原ボセンタンの有効性を評価する.
主な方法:
- 慢性的な全身から肺へのシャントリングのピッグレットモデルが確立されました.
- 動物はボセンタンまたはプラセボで治療され,血液動力学および組織学的に評価されました.
- ET-1,NOシンタゼ,VEGF,テンアシンの遺伝子およびタンパク質発現は,qPCRと免疫ヒストケミストリーを用いて分析された.
主要な成果:
- システムから肺へのシャントリングは,プラズマET-1,肺ET-1/ET(B) 受容体/VEGF発現,および肺動脈の圧力を増加させた.
- 動脈中枢の厚さが有意に増加し,肺高血圧の兆候である.
- ボセタン治療は,これらの血液動力学的および構造的変化を完全に防ぐことができました.
結論:
- 循環過剰によって引き起こされる実験的肺高血圧は,肺ET-1システムの活性化と因果的に関連しています.
- 二重のエンドセリン受容体対抗体ボセンタンは,このタイプの肺高血圧の発症を効果的に予防します.
関連する概念動画
01:30Pulmonary Hypertension: Classification and Pathogenesis
906
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
906
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
823
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
823
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
615
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
615
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
613
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
613
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
689
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
689
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
817
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
817